China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the National Medical Products Administration (NMPA) for an additional indication of its in-house developed Category 1 biologic product, xeligekimab. The anti-IL-17 antibody is now approved to treat ankylosing spondylitis (radiologically positive axial spondyloarthritis), following its initial approval in August of last year for moderate-to-severe plaque psoriasis.
Xeligekimab: Expanding Therapeutic Reach
The latest approval for xeligekimab marks a significant expansion of its therapeutic applications. Initially approved for treating moderate-to-severe plaque psoriasis, the drug has now been greenlit for ankylosing spondylitis, a chronic inflammatory disease affecting the spine and sacroiliac joints. This new indication enhances Genrix’s position in the autoimmune disease market.
Market Landscape for Anti-IL-17 Therapies
In China, the market for anti-IL-17 therapies includes similar products such as Novartis’ Cosentyx (secukinumab) and Eli Lilly’s Taltz (ixekizumab), both of which are indicated for plaque psoriasis. With the new approval, xeligekimab is poised to compete in the growing segment of IL-17 inhibitors targeting autoimmune conditions.-Fineline Info & Tech
Leave a Reply